VIZLIB
Vizlib, the data visualisation library for Qlik Sense, has today announced the acquisition of Climber Extensions. Providing a range of complementary extensions for Qlik Sense, the spin-off of Climber AB will support Vizlib’s vision of making data talk.
Widely known for the Custom Report and the Finance Report extensions for Qlik Sense, Climber Extensions is one of the leading providers in the Qlik ecosystem and part of Qlik’s Trusted Extensions Developer (TED) program. With a strong product portfolio and a global customer audience, the acquisition of Climber Extensions strengthens Vizlib’s position in the self-service analytics market. The move will also accelerate the development of the Vizlib Collaboration™ product by offering customers in-app commentary, write-back and chatting possibilities. Vizlib expects the acquisition to aid their mission in helping customers drive the adoption of data analytics across organisations.
“The decision to acquire Climber Extensions underlines Vizlib’s focus on delivering best-in-class solutions for our customers,” explains Martin Mahler, Vizlib’s CEO. “We are building on our longstanding relationship with Climber Extensions, a team that succeeded in developing intuitive, high-quality products in a short period of time. We will now be able to leverage a team of 28 people to explore new ways of streamlining our customers’ data analytics journey. This is an exciting time for us as we embark on a new growth path.”
Until a planned relaunch of Vizlib’s website, Climber Extensions will be offered as two extensions packages – Climber Self-Service™ & Climber Finance™ – complementing Vizlib’s own Vizlib Library™. Through a unique one-stop shopping experience, customers will be able to subscribe to either product via a unified subscription, benefiting from a joint support experience and a single vendor relationship.
“Being part of Vizlib will raise the game for Climber Extensions. They are a perfect match for us with their digital customer platform and a worldwide partner network,” says Michael Nordström, Climber Extensions CTO. “The effects of teaming up with Vizlib’s skilled developers can already be seen. We push and challenge each other, so the merge will lead to an even faster development of both new and existing extensions. Now, we are adding more exciting features to the Finance Report and Custom Report and are thrilled to share the results at Qlik's global conference, Qonnections 2019, in May.”
The financial details of the acquisition have not been disclosed.
---------------------------------------------------------------------------------------------------------------------------
ABOUT VIZLIB Established in 2016, Vizlib strives to provide best-in-class data visualisations library and data analytics experience for business users. With offices in London, Poznan and Stockholm, Vizlib is currently leading the Qlik ecosystem as a Qlik Technology Partner. Our feature-rich, intuitive plug & play extensions for BI tools empower data-driven organisations to go beyond their current analytics capabilities and uncover new, meaningful insights faster than ever before. We make data talk.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190415005411/en/
Contact:
Carolina Mistander Public Relations M: +46 (0) 723 52 35 09 E: Carolina.Mistander@vizlib.com www.vizlib.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom